Early Days

A beautiful day in San Francisco and although many of the meetings at this year's H&Q conference seemed to spill into the streets surrounding the St. Francis Hotel, with men in suits or casual attire mingling in groups of two and three on the sidewalks, the lobby and hallways of the Hotel are still packed full of industry executives looking to make things happen. That's right, my first impression of this year's conference, and perhaps indicative of what's to come in 2006: people want to do deal

By | January 10, 2006

A beautiful day in San Francisco and although many of the meetings at this year's H&Q conference seemed to spill into the streets surrounding the St. Francis Hotel, with men in suits or casual attire mingling in groups of two and three on the sidewalks, the lobby and hallways of the Hotel are still packed full of industry executives looking to make things happen. That's right, my first impression of this year's conference, and perhaps indicative of what's to come in 2006: people want to do deals. Many of the major pharmaceutical and big biotechnology companies seem interested in early stage therapeutic product opportunities ? even pre-proof of concept ? and are looking to grow either by corporate partnering or M&A, i.e. they are willing to bring products into their pipelines by any means necessary. The IPO market remains flat, which also suggests that the industry will see a higher level of corporate partnering and M&A activity. On the investor front, VC's seem more than willing to continue spending money....selectively. Anonymous Quote of the day: ?In a post-Vioxx world, it's not just about getting drugs approved; it's about getting the right drugs approved for the right patient populations.?

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech